alumis - Search News

Alumis draws Outperform at Oppenheimer

Alumis draws Outperform at Oppenheimer on valuation disconnect

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of $32 on Thursday, noting that despite the potential in its pipeline, the company continues to trade near its cash level.

ETF Daily News · 12h

Oppenheimer Begins Coverage on Alumis (NASDAQ:ALMS)

Oppenheimer assumed coverage on shares of Alumis (NASDAQ:ALMS – Free Report) in a research note published on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $32.00 price objective on the stock.

Business Insider · 3d

Alumis initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering

Fintel on MSN · 2d

Oppenheimer Initiates Coverage of Alumis (ALMS) with Outperform Recommendation

Fintel reports that on January 30, 2025, Oppenheimer initiated coverage of Alumis (NasdaqGS:ALMS) with a Outperform recommendation. Analyst Price Forecast Suggests 356.72% Upside As of January 29, 2025,

Hosted on MSN · 3d

Oppenheimer sets Alumis stock with Outperform, $32 target

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing oral solutions for inflammatory and autoimmune disorders.

2don MSN

Why Alumis (ALMS) Stock Is Advancing Today

Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...

Alumis Strengthens Leadership Team with Key Appointments

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

Alumis Inc. (NASDAQ:ALMS) Receives $26.83 Average Price Target from Analysts

Alumis Inc. (NASDAQ:ALMS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Six analysts have ...

news.stocktradersdaily2d

(ALMS) Pivots Trading Plans and Risk Controls

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Nasdaq1mon

Alumis announces Phase 1 data for CNS penetrant TYK2 inhibitor, A-005

Alumis (ALMS) announced data from a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics, PK, of single- and multiple-ascending doses of A-005, a potent, selective ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Alumis draws Outperform at Oppenheimer

Related topics